Improved Outcomes Seen With Lower 2021 KDIGO BP Target
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 17, 2023 -- The newly lowered Kidney Disease: Improving Global Outcomes (KDIGO) blood pressure (BP) target systolic BP (SBP) of <120 mm Hg is associated with improved outcomes compared with the 2012 KDIGO BP target, according to a study published online Aug. 4 in the Journal of Internal Medicine.
Cheol Ho Park, M.D., Ph.D., from Yonsei University in Seoul, South Korea, and colleagues examined the association between the 2021 KDIGO BP target and chronic kidney disease (CKD) progression and compared it to the 2012 KDIGO BP target among 1,724 individuals from Korea with CKD. The main exposure was BP status categorized according to the 2012 or 2021 KDIGO guideline.
The researchers found that during the 8,078 person-years of follow-up, composite kidney outcomes occurred in 37.7 percent of participants. The incidence rates were 55, 66.5, and 116.4 per 1,000 person-years for BP controlled within the 2021 and 2012 KDIGO targets and BP above both targets, respectively. In the multivariable cause-specific hazard model, hazard ratios for the composite outcome were 0.76 for BP controlled within the 2021 target and 1.36 for BP above both targets compared with BP controlled within the 2012 target only.
"Caution should be taken in implementing this new target in clinical practice, and further long-term interventional trials are required to clarify the renoprotective effects of lowering SBP to <120 mm Hg," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease
TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...
Women Face Worse Chronic Kidney Disease Management in Primary Care
MONDAY, May 20, 2024 -- Women receive worse primary care-based chronic kidney disease (CKD) management than men, according to a research letter published online May 16 in the...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.